LYON, France, Feb. 14 (UPI) -- French firm Sanofi pasteur said Wednesday it licensed Acambis' Japanese encephalitis vaccine ChimeriVaxTM-JE for up to 30 million euros.
Under the agreement, Sanofi pasteur gains marketing, distribution and certain manufacturing rights to ChimeriVaxTM-JE worldwide excluding India, the Indian subcontinent and the United States.
Acambis receives upfront and milestone payments of up to 30 million euros following approval of the vaccine in key endemic countries and the European Union. Acambis is also eligible to receive royalties on sales.
"Sanofi pasteur will further contribute to the fight against a devastating disease by bringing an innovative Japanese encephalitis vaccine to endemic countries," said Dave Williams, Sanofi's chief executive officer.
"We believe a single-dose vaccine will hold significant advantages for use in routine immunization programs in a region where several billion people live," Williams added.